PhD Neuroscientist | Clinical Research & Medical Affairs | Translating Science into Strategy
TBI research is moving into a new chapter. We’ve known for a long time that brain injury can set the stage for neurodegeneration, but actually tracking those molecular changes in patients has been a challenge. Part of the difficulty comes from the wide range of injury parameters (severity, frequency, mechanism) and the even wider range of sequelae that follow. No two TBIs look alike and that complexity has slowed progress in predicting outcomes and tailoring treatments. A recent review in Frontiers in Neurology (Giarratana AO, 2025) stood out to me because it shows how PET biomarkers can help bring order to that complexity: ✅ Amyloid and tau imaging tie TBI pathology to Alzheimer’s-like processes 🧠 Neuroinflammation tracers pick up on persistent microglial activation long after the injury 🔬 Metabolic and neurotransmitter PET shine a light on disrupted circuitry What I really like is the use of the term neurotheranostic — tools that don’t just describe pathology, but guide interventions. My research in TBI and neuroinflammation keeps pointing to the same truth: we need tools that bridge mechanism to medicine. Neurotheranostics feels like a step in that direction. The aim should be to benefit every patient from "mild" injuries to the most severe cases. 👉 Here’s the link if you want to take a look: https://lnkd.in/d4ygvvfM #Neuroscience #TraumaticBrainInjury #Neurotheranostics #Neurodegeneration #PETImaging #PrecisionMedicine #TranslationalResearch
PhD Neuroscientist | Clinical Research & Medical Affairs | Translating Science into Strategy
2wWhere do you see the biggest opportunity for neurotheranostics in TBI: risk stratification, patient selection, therapeutic monitoring, or something else entirely?